Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 16/20 | 1.00 |
| ▸ | PTK2B | Q14289 | 8/20 | 1.00 |
| ▸ | ULK1 | O75385 | 6/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 1/20 | 1.00 |
| ▸ | CDK7 | P50613 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060602 | 1.00 | PTK2 (1.00) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL29382158 | 1.00 | PTK2 (1.00) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL31732817 | 1.00 | PTK2 (1.00) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL17545007 | 0.96 | PTK2 (0.92) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL5209315 | 0.94 | PTK2 (0.88) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL3146424 | 0.93 | PTK2 (1.00) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL5212849 | 0.90 | PTK2B (0.82) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL17547558 | 0.90 | PTK2 (0.81) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL17544462 | 0.89 | PTK2 (0.91) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL17547472 | 0.89 | PTK2 (0.80) | PTK2PTK2BULK1CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190040448-A1 | METHODS OF DIAGNOSING AND TREATING B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | THE GENERAL HOSPITAL CORPORATION | 2019-02-07 | — | — | US | claimed |
| US-20160251696-A1 | METHODS OF DIAGNOSING AND TREATING B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | TUFTS MEDICAL CENTER | 2016-09-01 | — | — | US | claimed |
| WO-2015054477-A1 | METHODS OF DIAGNOSING AND TREATING B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | THE GENERAL HOSPITAL CORPORATION (US) | 2015-04-16 | — | — | WO | claimed |
| US-7235562-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2007-06-26 | — | — | US | claimed |
| EP-1758887-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Incorporated (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2005111016-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | claimed |
| US-20050256111-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| US-20240100051-A1 | Anti-Tumor Immunotherapy Enhancer | TSUKAMOTO NOBUO (JP) | 2024-03-28 | — | — | US | disclosed |
| EP-3700516-B1 | INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION | SONIC MASTER LTD (VG) | 2024-01-24 | — | — | EP | disclosed |
| US-11752150-B2 | Anti-tumor immunotherapy enhancer | NOBUO TSUKAMOTO (JP) | 2023-09-12 | — | — | US | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230130766-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2023-04-27 | — | — | US | disclosed |
| US-20100305099-A1 | DIAMINOPYRIDINES FOR THE TREATMENT OF DISEASES WHICH ARE CHARACTERISED BY EXCESSIVE OR ANOMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305099-A1 | DIAMINOPYRIDINES FOR THE TREATMENT OF DISEASES WHICH ARE CHARACTERISED BY EXCESSIVE OR ANOMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| WO-2009071535-A1 | DIAMINOPYRIDINES FOR THE TREATMENT OF DISEASES WHICH ARE CHARACTERISED BY EXCESSIVE OR ANOMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | WO | disclosed |
| US-7235562-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1758887-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Incorporated (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005111016-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256111-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040448-A1 | METHODS OF DIAGNOSING AND TREATING B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PTK2, BLK, BCL3 | PTK2 1/4885PTK2B 15/4885ULK1 1523/4885 |
| US-20230130766-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | ULK1, ULK2, ULK3 | PTK2 613/4885PTK2B 388/4885ULK1 1/4885 |
| US-20160251696-A1 | METHODS OF DIAGNOSING AND TREATING B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PTK2, BLK, BCL3 | PTK2 1/4885PTK2B 15/4885ULK1 1523/4885 |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | EPCAM, FABP2, TPMT | PTK2 1704/4885PTK2B 3922/4885ULK1 1709/4885 |
| US-20050256111-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | TYMS, TYMP, CCNA1 | PTK2 3610/4885PTK2B 3168/4885ULK1 3275/4885 |
| US-20100305099-A1 | DIAMINOPYRIDINES FOR THE TREATMENT OF DISEASES WHICH ARE CHARACTERISED BY EXCESSIVE OR ANOMAL CELL PROLIFERATION | BOD1L1, DPYD, MKI67 | PTK2 2418/4885PTK2B 1605/4885ULK1 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.